Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
826 stopped studies mapped to Malignant Female Reproductive System Neoplasm and descendants · 86% state a reason
Over the 826 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare… | Phase 2 | suspended | Apr 20, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT07146919 | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer(ANGELICA) | Phase 1 / Phase 2 | withdrawn | Aug 28, 2025 | Centre Leon Berard | Molecule not available from the laboratory | Other (stated, no rule matched) |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or… | Phase 2 | terminated | Aug 22, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | study closed early due to slow accrual | Enrollment / accrual |
| NCT06760702 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109…(TEJAS-2) | Phase 2 | terminated | Jan 7, 2025 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT05397093 | ITIL-306 in Advanced Solid Tumors | Phase 1 | terminated | May 31, 2022 | Instil Bio | The study was terminated early due to discontinuation of development of the investigational program | Other (stated, no rule matched) |
| NCT05866679 | Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging | Phase 1 | suspended | May 19, 2023 | M.D. Anderson Cancer Center | Suspension | Other (stated, no rule matched) |
| NCT01164150 | Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using… | Phase 2 | terminated | Jul 16, 2010 | Cancer Trials Ireland | not stated | Not stated |
| NCT07000344 | A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen… | N/A | terminated | Jun 2, 2025 | Peking Union Medical College Hospital | Results failed to achieve the anticipated effect. | Other (stated, no rule matched) |
| NCT07035067 | Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and… | — | terminated | Jun 24, 2025 | PeriPharm | Recruitment | Enrollment / accrual |
| NCT03894215 | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in… | Phase 2 | terminated | Mar 28, 2019 | Agenus Inc. | Sponsor strategic decision | Sponsor / business decision |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT05036681 | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable… | Phase 2 | terminated | Sep 8, 2021 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and… | Phase 1 | terminated | Feb 5, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03922776 | Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After…(TILsOV) | N/A | terminated | Apr 22, 2019 | Centre Oscar Lambret | End of recruiting period | Enrollment / accrual |
| NCT04016142 | Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced…(ACCRAPAN) | Phase 2 | terminated | Jul 11, 2019 | Centre Oscar Lambret | The study is discontinued because of recruitment failure, and for strategic reason (competitive… | Enrollment / accrual |
| NCT04651127 | Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Dec 3, 2020 | Sun Yat-sen University | Five patients were enrolled in the study, but no treatment response was observed and all the… | Efficacy / futility |
| NCT07211204 | Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular… | N/A | withdrawn | Oct 7, 2025 | Timser SAPI de CV | The study did not start, i.e., no participants were enrolled, because the Mexican Regulatory… | Enrollment / accrual |
| NCT05192837 | Preoperative Smoking Cessation in Patients Undergoing Surgery(PORTICO) | N/A | terminated | Jan 14, 2022 | Luzerner Kantonsspital | The study is being terminated prematurely due to insufficient participant recruitment. | Enrollment / accrual |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or… | Phase 1 | terminated | Oct 3, 2024 | Accent Therapeutics | The study was terminated by sponsor based on the adverse event profile. | Safety / toxicity |
| NCT06546553 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the… | Phase 1 | terminated | Aug 9, 2024 | Pfizer | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT07226102 | Virtual Mental Health Intervention to Address Fear of Progression for Women With High… | N/A | withdrawn | Nov 10, 2025 | City of Hope Medical Center | slow accrual | Enrollment / accrual |
| NCT05756907 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant… | Phase 1 / Phase 2 | terminated | Mar 7, 2023 | Sonnet BioTherapeutics | Failed to meet efficacy endpoint criteria, despite lack of safety concerns | Safety / toxicity |
| NCT05850663 | Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer | N/A | withdrawn | May 9, 2023 | University of Oklahoma | Study withdrawn due to lack of accrual. | Enrollment / accrual |
| NCT06457997 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Phase 1 | terminated | Jun 13, 2024 | Pheon Therapeutics | The study was terminated by Sponsor for strategic reasons. | Sponsor / business decision |
| NCT05357027 | HPV16 E6 TCR T Cells for Cervical Carcinoma | Phase 1 / Phase 2 | terminated | May 2, 2022 | TCRCure Biopharma Ltd. | Study terminated due to strategic portfolio decision to reallocate resources to higher-priority… | Sponsor / business decision |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT05082025 | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected… | Phase 2 | terminated | Oct 18, 2021 | M.D. Anderson Cancer Center | Copanlisib development was discontinued by Bayer following withdrawal of copanlisib in relapsed… | Other (stated, no rule matched) |
| NCT05481645 | Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib… | Phase 2 | terminated | Aug 1, 2022 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns. | Safety / toxicity |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations… | Phase 2 | terminated | Jun 27, 2024 | Lipomedix Pharmaceuticals Inc. | Sponsor decision | Sponsor / business decision |
| NCT02948426 | Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b)… | Phase 1 | terminated | Oct 28, 2016 | National Cancer Institute (NCI) | Study was closed to accrual due to lack of drug supply. | Drug supply |
| NCT01048853 | Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer | N/A | terminated | Jan 14, 2010 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT06545617 | A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum… | Phase 1 / Phase 2 | withdrawn | Aug 9, 2024 | Bio-Thera Solutions | Reconsideration of the subsequent international development of BAT8006 | Other (stated, no rule matched) |
| NCT03189108 | Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors | — | terminated | Jun 16, 2017 | National Cancer Institute (NCI) | PI left NIH | Investigator |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable… | Phase 1 | withdrawn | Oct 3, 2024 | City of Hope Medical Center | no resource | Other (stated, no rule matched) |
| NCT04000477 | Comparison of 2 Types of Cervical Specimens in Patients With a Pathological Screening…(ENDOCOL) | N/A | terminated | Jun 27, 2019 | University Hospital, Lille | default inclusion | Other (stated, no rule matched) |
| NCT06866951 | A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent… | Phase 2 / Phase 3 | withdrawn | Mar 10, 2025 | Women's Hospital School Of Medicine Zhejiang University | no participants enrolled | Enrollment / accrual |
| NCT05454358 | Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP | Phase 2 / Phase 3 | terminated | Jul 12, 2022 | Fudan University | No enough participants | Other (stated, no rule matched) |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian,… | Phase 2 | terminated | Feb 18, 2015 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | Phase 1 | terminated | Feb 23, 2022 | Blueprint Medicines Corporation | This trial was terminated prior to the initiation of Phase 2 for reasons not due to safety concerns. | Safety / toxicity |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors… | Phase 2 | terminated | Aug 7, 2020 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business reasons | Sponsor / business decision |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients… | Phase 1 | terminated | Feb 23, 2022 | Nuvation Bio Inc. | The Sponsor has achieved its objectives. | Other (stated, no rule matched) |
| NCT05798611 | Study of ART0380 in Patients With Biologically Selected Solid Tumors(ARTIST) | Phase 2 | terminated | Apr 4, 2023 | Artios Pharma Ltd | Sponsor decision, not for reasons affecting the benefit-risk balance. | Sponsor / business decision |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | Phase 2 | terminated | Dec 27, 2021 | Tempus AI | Recruitment challenges | Enrollment / accrual |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced… | Phase 1 | terminated | May 9, 2017 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 4, 2026source: clinicaltrials